These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 22243765)

  • 1. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
    J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.
    Matsukura S; Knowles SR; Walsh S; Shear NH
    Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single cycle of rituximab for the treatment of severe pemphigus.
    Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
    N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose rituximab is effective in pemphigus.
    Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
    Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
    Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
    Cho HH; Jin SP; Chung JH
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients.
    Leshem YA; Hodak E; David M; Anhalt GJ; Mimouni D
    J Am Acad Dermatol; 2013 Mar; 68(3):404-11. PubMed ID: 23044076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable remission of pemphigus with a fixed-dose rituximab protocol.
    Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
    JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients.
    Kim JH; Kim YH; Kim MR; Kim SC
    Br J Dermatol; 2011 Sep; 165(3):646-51. PubMed ID: 21574976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.
    Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U
    Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.
    Ingen-Housz-Oro S; Valeyrie-Allanore L; Cosnes A; Ortonne N; Hüe S; Paul M; Wolkenstein P; Chosidow O
    JAMA Dermatol; 2015 Feb; 151(2):200-3. PubMed ID: 25354242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
    Feldman RJ; Christen WG; Ahmed AR
    Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations.
    Craythorne E; du Viver A; Mufti GJ; Warnakulasuriya S
    J Oral Pathol Med; 2011 Sep; 40(8):616-20. PubMed ID: 21385212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
    Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
    Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pemphigus vulgaris with brief, high-dose intravenous glucocorticoids.
    Werth VP
    Arch Dermatol; 1996 Dec; 132(12):1435-9. PubMed ID: 8961871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful use of rituximab in the treatment of childhood and juvenile pemphigus.
    Vinay K; Kanwar AJ; Sawatkar GU; Dogra S; Ishii N; Hashimoto T
    J Am Acad Dermatol; 2014 Oct; 71(4):669-75. PubMed ID: 25022850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.